| 1 |
28185715 | Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | 2017 Mar |
1 |
| 2 |
28219664 | Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea. | 2017 Apr 15 |
1 |
| 3 |
25607338 | The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. | 2015 May |
1 |
| 4 |
25964889 | Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial. | 2015 Apr |
2 |
| 5 |
26089929 | The effect of pioglitazone on circulating interleukin-10 and tumor necrosis factor-alpha levels in a patient with metabolic syndrome: A randomized, double-blind controlled trial. | 2015 Jan |
1 |
| 6 |
24769306 | PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia. | 2014 Jun |
1 |
| 7 |
25025992 | Pioglitazone, a peroxisome proliferator-activated receptor γ activator, suppresses coronary spasm. | 2014 Dec |
1 |
| 8 |
25194409 | Effects of pioglitazone on blood glucose and inflammatory markers of diabetic kidney transplant patients: a randomized controlled trial. | 2014 Sep |
2 |
| 9 |
23359066 | Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. | 2013 Feb |
2 |
| 10 |
23524525 | Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. | 2013 Sep |
1 |
| 11 |
23710164 | Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial. | 2013 |
1 |
| 12 |
23807528 | Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. | 2013 Nov-Dec |
1 |
| 13 |
24229459 | The potential role of ‘non-rheumatic’ therapies in rheumatic disease. | 2013 |
1 |
| 14 |
24252844 | The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis. | 2013 Nov 19 |
1 |
| 15 |
21950726 | Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance. | 2012 Mar |
1 |
| 16 |
21993383 | Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial. | 2012 Jan |
1 |
| 17 |
20961967 | Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. | 2011 Jan |
1 |
| 18 |
21211686 | Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. | 2011 Jan 11 |
1 |
| 19 |
21255215 | Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial. | 2011 May |
2 |
| 20 |
21339857 | Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study). | 2011 Feb 7 |
1 |
| 21 |
21999871 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. | 2011 Oct |
1 |
| 22 |
22029000 | Pioglitazone: Indian perspective. | 2011 Oct |
1 |
| 23 |
19787290 | Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes. | 2010 Dec |
1 |
| 24 |
20670183 | Pioglitazone: beyond glucose control. | 2010 Aug |
1 |
| 25 |
20831680 | Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. | 2010 Oct |
1 |
| 26 |
20926154 | The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis. | 2010 Dec |
3 |
| 27 |
21122063 | Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. | 2010 Dec |
1 |
| 28 |
18758684 | Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. | 2009 Mar |
1 |
| 29 |
19096190 | Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. | 2009 Feb |
1 |
| 30 |
17768592 | Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. | 2008 Mar |
1 |
| 31 |
18413496 | Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. | 2008 Apr 22 |
1 |
| 32 |
18577834 | Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. | 2008 Jul |
1 |
| 33 |
17239709 | Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. | 2007 Jan 23 |
5 |
| 34 |
17379017 | Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. | 2007 Apr |
2 |
| 35 |
17556865 | Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes. | 2007 Apr |
1 |
| 36 |
16159895 | Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. | 2006 Mar |
1 |
| 37 |
16461819 | Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. | 2006 Feb 14 |
2 |
| 38 |
16939632 | C-reactive protein (CRP)-lowering agents. | 2006 Spring |
1 |
| 39 |
16306801 | Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. | 2005 Dec |
2 |
| 40 |
12667961 | Vascular smooth muscle cell activation by C-reactive protein. | 2003 Apr 1 |
1 |
| 41 |
12730556 | Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. | 2003 Jun |
1 |
| 42 |
12941708 | Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. | 2003 Sep |
1 |